Connect Biopharma (CNTB) investor relations material

Company overview and business model

• Headquartered in San Diego, California, operates as a clinical-stage biopharmaceutical company focused on asthma and COPD therapies, advancing rademikibart, a next-generation antibody targeting IL-4Rα.

• Incorporated in the Cayman Islands as a holding company, with operations conducted through subsidiaries, including entities in the PRC.

Risk factors and disclosures

• Investment involves risks, including potential loss of investment, unpredictable economic, business, regulatory, and competitive factors, and historical performance not being indicative of future results.

• Enforcement of civil liabilities may be limited due to incorporation in the Cayman Islands and operations in the PRC, with uncertainties in recognition of foreign judgments.

• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling securityholders; all registration expenses are borne by the company, while selling expenses are borne by the securityholders.